Cohort profile: Evaluation of the Methods and Management of Acute Coronary Events (EMMACE) Longitudinal Cohort

Theresa Munyombwe; Tatendashe B Dondo; Marlous Hall; Ramesh Nadarajah; Ben Hurdus; Suleman Aktaa; Mohammad Haris; Adam Keeley; Robert West; Alistair Hall; Paul Norman; Chris P Gale

doi:10.1093/ehjqcco/qcad040

Cohort profile: Evaluation of the Methods and Management of Acute Coronary Events (EMMACE) Longitudinal Cohort

Eur Heart J Qual Care Clin Outcomes. 2023 Aug 7;9(5):442-446. doi: 10.1093/ehjqcco/qcad040.

Authors

Theresa Munyombwe^{1

2}, Tatendashe B Dondo^{1

2}, Marlous Hall^{1

2}, Ramesh Nadarajah^{1

2

3}, Ben Hurdus², Suleman Aktaa^{2

3}, Mohammad Haris^{2

3}, Adam Keeley², Robert West⁴, Alistair Hall^{1

3}, Paul Norman⁵, Chris P Gale^{1

2

3}

Affiliations

¹ Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, 6 Clarendon Way, LS2 9JT Leeds, UK.
² Leeds Institute for Data Analytics, University of Leeds, LS2 9JT Leeds, UK.
³ Department of Cardiology, Leeds Teaching Hospitals NHS Trust, LS1 3EX Leeds, UK.
⁴ Leeds Institute of Health Sciences, University of Leeds, LS2 9JT Leeds, UK.
⁵ School of Geography, University of Leeds, LS2 9JT Leeds, UK.

Abstract

Aims: The Evaluation of the Methods and Management of Acute Coronary Events (EMMACE) longitudinal cohort study aims to investigate health trajectories of individuals following hospitalization for myocardial infarction (MI).

Methods and results: EMMACE is a linked multicentre prospective cohort study of 14 899 patients with MI admitted to 77 hospitals in England who participated in the EMMACE-3 and -4 studies between 1st November 2011 and 24th June 2015. Long-term follow-up of the EMMACE cohorts was conducted through the EMMACE-XL (27th September 2020 to 31st March 2022) and EMMACE-XXL (1st July 2021 to 1st July 2023) studies. EMMACE collected individual participant data for health-related quality of life (HRQoL) measured by three-level EuroQol five-dimension and visual analogy scale at admission, 1 month, 6 months, 12 months, and 10 years follow-up, as well as medications, medication adherence, beliefs about medicines, Satisfaction with Information about Medicines Scale, and illness perceptions. Participant data were deterministically linked to the Myocardial Infarction National Audit Project (MINAP) for information on baseline treatments and comorbidities, Hospital Episode Statistics Admitted Patient Care (for cause-specific hospitalization data), and the Office for National Statistics (for mortality data) up to 2020.

Conclusion: EMMACE is a nationwide prospective cohort that will provide unique insights into fatal and non-fatal outcomes, medication adherence, and HRQoL following MI.Trial registration: ClinicalTrials.gov NCT01808027 and NCT01819103.

Keywords: Cohort; Electronic health records; Health-related quality of life; Hospitalizations; Longitudinal data; Medications; Myocardial infarction; Outcomes.

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Hospitalization
Humans
Longitudinal Studies
Myocardial Infarction* / epidemiology
Myocardial Infarction* / therapy
Prospective Studies
Quality of Life*

Associated data

ClinicalTrials.gov/NCT01808027
ClinicalTrials.gov/NCT01819103

Abstract

Publication types

MeSH terms

Associated data

Grants and funding